TABLE 3.

Liposomal formulations of anticancer drugs in phase II clinical trials

Product Name	Encapsulated Drugs	Type of Liposomes	Indications	Lipid Composition	Particle Size	Status	Reference
					nm
CPX-1	Irinotecan and floxuridine (1:1)	ULVs	Advanced solid tumors, including colorectal cancer	DSPC, DSPG, and cholesterol	100	Phase II	NCT00361842a (accessed on Apr 14, 2015); Batist et al. (2009)
EndoTAG-1	Paclitaxel	Cationic liposomes	Solid tumors	DOTAP, DOPC	180–200	Phase II	Fasol et al. (2012); Lohr et al. (2012); Awada et al. (2014)
LEP-ETU	Paclitaxel	Anionic liposomes	Metastatic breast cancer	DMPC, DOPC, DSPC, cholesterol, and cardiolipin	100–160	Phase II	NCT01190982a (accessed on Apr 15, 2015); Zhang et al. (2005); Slingerland et al. (2013)
MBP-426	Oxaliplatin	Tf-conjugated liposomes	Gastric, gastroesophageal, esophageal adenocarcinomas	DSPC, DSPE-PEG2000Da, cholesterol and Tf -conjugated NGPE	180	Phase II	Suzuki et al. (2008); van der Meel et al. (2013)
OSI-211	Lurtotecan	SUVs	NSCLC, breast, colorectal, ovarian, head and neck cancers	Soy PC and cholesterol	100	Phase II	Gamucci et al. (2000); Duffaud et al. (2004); Seiden et al. (2004)

^aClinicalTrials.gov identifier

DSPG, 1,2-distearoyl-sn-glycerol-3-phospho-(1′-rac-glycerol); NGPE, N-glutaryl phosphatidylethanolamine; NSCLC, non-small cell lung cancer; Tf, transferrin